Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in Schizophrenia
Status:
Terminated
Trial end date:
2018-07-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy of combining open-label extended
release bupropion (flexible dosing up to 450mg target) and naltrexone (37.5mg) versus
Bupropion and placebo along with a daily 500 calorie reduction diet recommendation for weight
and health risk reduction in 40 overweight/obese individuals with schizophrenia.